WHO approves first mpox diagnostic test for emergency use
Health & Science
By
Xinhua
| Oct 04, 2024
The World Health Organization (WHO) said on Friday that it has approved the first diagnostic test for mpox, marking a significant milestone in expanding global access to mpox testing.
The approval comes as Africa continues to struggle with limited testing capacity, which fueled the spread of the virus. Over 30,000 suspected mpox cases have been reported across the continent in 2024, with the Democratic Republic of the Congo (DRC), Burundi, and Nigeria being the most affected.
In the DRC, only 37 per cent of suspected cases have been tested this year, according to the global health agency.
The test, known as Alinity m MPXV assay, will boost diagnostic capacity in countries facing mpox outbreaks, where rapid and accurate testing is crucial.
READ MORE
Kenya misses out on Sh125b World Bank project
Inside beer distribution dispute threatening Diageo's exit plan
Sale of strategic assets, infrastructure fund offer new fodder for Ruto critics
JKIA unveils airport makeover plan without funding clarity
Adani knocks again after losing first round in Sh258b airport deal
KTDA inks deal with KIPPRA to accelerate market-driven transformation
Why Mbadi wants IEBC to reduce Sh64b election budget
How Kenyans lost Sh10bn through shadowy investments
Kenyan startups outshine Africa with three major innovation wins
The Alinity m MPXV assay is a real-time PCR test designed to detect mpox virus DNA from human skin lesion swabs, enabling laboratory and health workers to confirm cases quickly.
"This first mpox diagnostic test listed under the Emergency Use Listing procedure represents a significant milestone in expanding testing availability in affected countries," said Yukiko Nakatani, WHO's assistant director-general for access to medicines and health products.